This page separates reported trial results from statistical interpretation. Numerical results and trial-design facts are restricted to the ClinicalTrials.gov record. Where the registry does not report a detail, it is not reconstructed from outside sources.
1. Trial at a Glance
EVOLVE-1 was a completed phase 3, randomized, double-masked, parallel-group trial evaluating galcanezumab versus placebo in migraine. The registry reports an enrollment of 862 participants and three arms, with galcanezumab 120 mg, galcanezumab 240 mg, and placebo represented in the posted safety data.
| Feature | EVOLVE-1 |
|---|---|
| Trial name | EVOLVE-1 |
| Brief title | Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study |
| Phase | Phase 3 |
| Condition | Migraine |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Primary purpose | Treatment |
| Enrollment | 862 |
| Interventions | Galcanezumab; placebo |
| Results posted | Yes |
| Outcome measures posted | 10 |
| Statistical analyses posted | 22 |
| ClinicalTrials.gov | NCT02614183 |
2. Clinical Question
The statistical question is whether treatment with galcanezumab is associated with a different change in migraine-related outcomes than placebo over the registered assessment periods.
Population
Participants enrolled in the phase 3 EVOLVE-1 study for the prevention of episodic migraine.
Intervention
Galcanezumab, represented in the registry results by 120 mg and 240 mg treatment groups.
Comparator
Placebo.
Primary question
How did galcanezumab compare with placebo for the overall mean change from baseline in the number of monthly migraine headache days from baseline through Month 6?
3. Trial Design
Galcanezumab 120 mg
- Galcanezumab treatment arm
- Included in the primary efficacy comparison with placebo
- Serious adverse events: 6/206 during the treatment phase
- Serious adverse events: 4/183 during the post-treatment phase
Galcanezumab 240 mg
- Galcanezumab treatment arm
- Included in the primary efficacy comparison with placebo
- Serious adverse events: 0/220 during the treatment phase
- Serious adverse events: 4/185 during the post-treatment phase
Placebo
- Placebo comparator arm
- Used as the reference group for the posted efficacy comparisons
- Serious adverse events: 5/432 during the treatment phase
- Serious adverse events: 2/372 during the post-treatment phase
4. Trial Timing and Registry Status
Study start
The registry lists the study start date as 2015-11-30.
Primary completion
The registry lists the primary completion date as 2017-03-22.
Registry status
The ClinicalTrials.gov record identifies EVOLVE-1 as completed and reports posted results.
5. Primary Endpoint
| Endpoint | Registry definition / time frame | Analysis |
|---|---|---|
| Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days | Baseline, Month 1 through Month 6 | Mixed Models Analysis; mean difference |
The registry defines a Migraine Headache Day (MHD) as a calendar day on which a migraine headache or probable migraine headache occurred. The posted primary analysis uses the longitudinal outcome across baseline and Month 1 through Month 6 rather than reducing the entire study to a single unadjusted endpoint measurement.
6. Statistical Methodology
Mixed-effects model for repeated measurements
The primary endpoint was measured longitudinally, with observations spanning baseline through Month 6. The registry reports a Mixed Models Analysis, normalized here as a mixed-effects model.
A mixed-effects model is useful when the same participants contribute multiple measurements over time. Rather than treating each time point as an unrelated analysis, the model can represent the repeated-measure structure and estimate treatment differences while using the longitudinal information available from participants with qualifying observations.
Here, Yij represents an outcome measured for participant i at time j. The exact covariance structure and fixed-effect specification are not provided in the ClinicalTrials.gov record and therefore are not reconstructed here.
Mean difference
The primary treatment effect is reported as a mean difference in final values. The direction matters. Because the outcome is change in monthly migraine headache days, a negative treatment-versus-placebo difference indicates a more negative change in the galcanezumab group relative to placebo.
For this endpoint, a negative estimate indicates a greater reduction in monthly migraine headache days for the galcanezumab group under the reported comparison.
Odds ratios for responder outcomes
The registry also reports odds ratios for binary responder endpoints defined by reductions from baseline of at least 50%, at least 75%, and 100% in monthly migraine headache days. An odds ratio greater than 1 means the estimated odds of meeting the specified responder criterion were higher in the galcanezumab group than in placebo under the reported comparison.
Fisher exact test
For anti-drug antibody outcomes, the registry reports Fisher exact testing. This is an exact method for comparing categorical proportions between two groups and is particularly useful when event counts are sparse enough that large-sample approximations may be unreliable.
Superiority framework
The statistical analyses posted on ClinicalTrials.gov are classified as superiority. The reported primary comparisons therefore ask whether the observed outcome differs between galcanezumab and placebo, rather than whether galcanezumab falls within a prespecified non-inferiority margin.
7. Primary Results: Monthly Migraine Headache Days
Galcanezumab 120 mg vs Placebo
Mean difference in change from baseline
95% CI: -2.48 to -1.37 · P < .001
Mixed Models Analysis; baseline, Month 1 through Month 6
The reported mean difference of -1.92 days means that the modeled overall mean change in monthly migraine headache days was 1.92 days more negative for the galcanezumab 120 mg group than for placebo, according to the registry's treatment comparison.
It does not mean that every participant experienced exactly 1.92 fewer migraine headache days. It is a group-level estimated difference from a longitudinal model.
The 95% confidence interval from -2.48 to -1.37 describes statistical uncertainty around the estimated mean difference under the analysis framework. It does not describe the range of individual treatment responses.
The P < .001 value addresses the statistical evidence against the null hypothesis specified for the comparison; it is not a measure of the magnitude or clinical importance of the effect. Effect size and statistical evidence should be considered separately.
Because the endpoint was analyzed longitudinally, interpretation depends on the mixed-effects model specification and the assumptions underlying the handling of repeated observations and missingness. Those model details are not fully reported in the ClinicalTrials.gov record.
Galcanezumab 240 mg vs Placebo
Mean difference in change from baseline
95% CI: -2.31 to -1.20 · P < .001
Mixed Models Analysis; baseline, Month 1 through Month 6
The reported mean difference of -1.76 days indicates a more negative modeled change in monthly migraine headache days for the galcanezumab 240 mg group than for placebo.
The estimate is a population-level treatment comparison, not an individual prediction. A participant's observed change can be substantially different from the group mean difference.
The 95% CI of -2.31 to -1.20 quantifies uncertainty around the estimated group difference. Its width provides information about precision; it does not indicate that individual effects must lie inside the interval.
The P < .001 result indicates strong statistical evidence for a difference under the reported superiority analysis. It should not be interpreted as a percentage probability that the treatment works, nor as a measure of effect size.
The two primary comparisons involve two galcanezumab doses against placebo. The ClinicalTrials.gov record does not describe an alpha-allocation or multiplicity-adjustment procedure for these two primary comparisons, so no additional multiplicity conclusion is imposed here.
| Primary comparison | Estimate | 95% CI | P-value | Method |
|---|---|---|---|---|
| Placebo vs Galcanezumab 120 mg | -1.92 | -2.48 to -1.37 | <.001 | Mixed-effects model |
| Placebo vs Galcanezumab 240 mg | -1.76 | -2.31 to -1.20 | <.001 | Mixed-effects model |
8. Secondary Efficacy Results: Responder Outcomes
The registry reports a secondary endpoint measuring the mean percentage of participants with reductions from baseline of at least 50%, at least 75%, and 100% in monthly migraine headache days. The analyses posted on ClinicalTrials.gov report odds ratios for individual responder thresholds.
| Responder threshold | Comparison | Odds ratio | 95% CI |
|---|---|---|---|
| Reduction ≥50% | Galcanezumab 120 mg vs placebo | 2.63 | 2.05 to 3.37 |
| Reduction ≥50% | Galcanezumab 240 mg vs placebo | 2.48 | 1.94 to 3.18 |
| Reduction ≥75% | Galcanezumab 120 mg vs placebo | 2.65 | 2.04 to 3.45 |
| Reduction ≥75% | Galcanezumab 240 mg vs placebo | 2.62 | 2.01 to 3.41 |
| Reduction =100% | Galcanezumab 120 mg vs placebo | 2.80 | 1.96 to 4.01 |
| Reduction =100% | Galcanezumab 240 mg vs placebo | 2.61 | 1.81 to 3.75 |
An odds ratio of 2.63, for example, means that the estimated odds of meeting the ≥50% reduction criterion were 2.63 times the corresponding odds in the placebo group for the reported galcanezumab 120 mg comparison.
An odds ratio is not a risk ratio. If the responder outcome is common, the odds ratio can be farther from 1 than the corresponding ratio of probabilities. Without the underlying responder counts, the odds ratios should not be converted into absolute response percentages.
The confidence intervals provide information about precision. For the ≥50% endpoint, the intervals are 2.05 to 3.37 for 120 mg and 1.94 to 3.18 for 240 mg. These intervals describe uncertainty around the odds-ratio estimates rather than variability among individual participants.
9. Secondary Quality-of-Life Result: MSQ Role Function Restrictive Domain
| Comparison | Mean difference | 95% CI | P-value | Method |
|---|---|---|---|---|
| Galcanezumab 120 mg vs placebo | 7.74 | 5.20 to 10.28 | <.001 | Mixed-effects model |
| Galcanezumab 240 mg vs placebo | 7.40 | 4.83 to 9.97 | <.001 | Mixed-effects model |
The endpoint was Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain, measured from baseline through Month 4 through Month 6. Both reported treatment comparisons used mixed-effects models and a mean difference in final values.
These estimates describe differences in the change in a quality-of-life scale between randomized treatment groups. They should not be interpreted as percentages or as the proportion of participants achieving a particular clinically meaningful threshold, because the registry analysis reports mean differences rather than responder proportions.
10. Secondary Migraine-Related Outcomes
| Endpoint | Comparison | Estimate | 95% CI | P-value |
|---|---|---|---|---|
| Overall Mean Change From Baseline in Monthly Migraine Headache Days Requiring Medication for Acute Treatment of Migraine or Headache | Galcanezumab 120 mg vs placebo | -1.81 | -2.28 to -1.33 | <.001 |
| Overall Mean Change From Baseline in Monthly Migraine Headache Days Requiring Medication for Acute Treatment of Migraine or Headache | Galcanezumab 240 mg vs placebo | -1.61 | -2.09 to -1.14 | <.001 |
| Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) Rating | Galcanezumab 120 mg vs placebo | -0.32 | -0.52 to -0.12 | <.001 |
| Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) Rating | Galcanezumab 240 mg vs placebo | -0.28 | -0.48 to -0.07 | <.001 |
| Overall Mean Change From Baseline in Headache Hours | Galcanezumab 120 mg vs placebo | -13.98 | -18.99 to -8.97 | <.001 |
| Overall Mean Change From Baseline in Headache Hours | Galcanezumab 240 mg vs placebo | -13.64 | -18.68 to -8.60 | <.001 |
| Mean Change From Baseline on MIDAS Total Score | Galcanezumab 120 mg vs placebo | -6.29 | -9.45 to -3.13 | <.001 |
| Mean Change From Baseline on MIDAS Total Score | Galcanezumab 240 mg vs placebo | -5.19 | -8.39 to -1.98 | <.001 |
11. Why the Longitudinal Analysis Matters
The primary endpoint was not simply a single post-treatment migraine-day measurement. It was defined as an overall mean change from baseline across baseline and Month 1 through Month 6. This creates a repeated-measures statistical problem: each participant can contribute multiple observations, and those observations are naturally related because they come from the same person.
More information per participant
A longitudinal model can use repeated measurements rather than discarding all but one observation per participant.
Within-person correlation
Repeated measurements from the same participant are generally not statistically independent. Mixed-effects models are designed to accommodate that structure.
Change from baseline
The treatment effect is framed around change rather than simply comparing an isolated follow-up value.
Missing observations
Longitudinal models can be useful when follow-up measurements are incomplete, although the validity of the resulting inference depends on the missing-data assumptions and model specification.
12. Statistical Methods Explained
Why was a mixed-effects model used?
The primary outcome was collected repeatedly from baseline through Month 6. A mixed-effects model is appropriate for this type of longitudinal structure because it can represent treatment, time, and repeated observations within participants while accounting for the correlation among observations from the same individual. The exact model specification is not reported in the ClinicalTrials.gov record, so the educational explanation should not be mistaken for a reconstruction of the full statistical analysis plan.
What does a mean difference of -1.92 mean?
For the 120 mg comparison, the reported mean difference was -1.92 days. Because the endpoint is change from baseline in monthly migraine headache days, the negative sign indicates that the modeled change was more negative in the galcanezumab group than in placebo by 1.92 days. It is a difference between group-level estimated means, not a statement that every participant had exactly the same change.
What does the 95% confidence interval tell us?
The interval from -2.48 to -1.37 quantifies uncertainty around the 120 mg mean-difference estimate under the reported analysis framework. A narrower interval generally indicates greater statistical precision than a wider interval, but the interval is not a range containing 95% of individual treatment effects.
What does an odds ratio of 2.63 mean?
For the ≥50% responder threshold, an odds ratio of 2.63 means the estimated odds of meeting that responder criterion were 2.63 times the odds under placebo for the reported 120 mg comparison. Odds are not probabilities, so the estimate cannot be read as "2.63 times as many participants responded."
Why use Fisher exact testing for anti-drug antibodies?
Anti-drug antibody outcomes are binary, and the relevant positive-event counts can be relatively sparse. Fisher exact testing calculates an exact probability for a two-group categorical comparison rather than relying on a large-sample approximation. The registry specifically reports Fisher exact testing for these analyses.
Why doesn't P < .001 tell us the size of the treatment effect?
A P-value describes the statistical evidence against a null hypothesis under the specified testing framework. It does not measure clinical magnitude. In EVOLVE-1, the magnitude is better described by the mean difference, odds ratio, and corresponding confidence interval, while the P-value addresses a different question about statistical evidence.
Why should the two primary dose comparisons be considered separately?
The ClinicalTrials.gov record contains two primary analyses: galcanezumab 120 mg versus placebo and galcanezumab 240 mg versus placebo. Each has its own estimate and confidence interval. Because the ClinicalTrials.gov record does not specify an alpha-allocation or multiplicity procedure for these two comparisons, the page does not claim that the reported P-values have been adjusted for testing both doses.
13. Anti-Drug Antibody Analyses
The registry reports the percentage of participants developing anti-drug antibodies (ADA) to galcanezumab from Month 1 through Month 6. The analysis population required at least one non-missing ADA test result during both the baseline and post-baseline periods.
| ADA endpoint | Comparison | Method | P-value |
|---|---|---|---|
| TE ADA Positive | Galcanezumab 120 mg vs placebo | Fisher exact test | <.160 |
| TE ADA Positive | Galcanezumab 240 mg vs placebo | Fisher exact test | .020 |
| Neutralizing Antibodies | Galcanezumab 120 mg vs placebo | Fisher exact test | .131 |
| Neutralizing Antibodies | Galcanezumab 240 mg vs placebo | Fisher exact test | .009 |
These are categorical comparisons rather than estimates of treatment effect expressed as mean differences. The registry supplies P-values but no corresponding effect estimates or confidence intervals for these ADA analyses.
A P-value such as .020 should not be converted into an estimated probability that the treatment caused an antibody response. The test evaluates the observed categorical data under its specified null framework.
Because the ClinicalTrials.gov record contains multiple ADA analyses, the individual nominal P-values should not automatically be treated as independently confirmatory without knowing the prespecified multiplicity strategy.
14. Safety Results
The ClinicalTrials.gov record reports serious adverse events separately for the treatment and post-treatment phases. These counts are presented as affected participants divided by participants at risk.
| Arm | Treatment phase | Post-treatment phase |
|---|---|---|
| Placebo | 5/432 | 2/372 |
| Galcanezumab 120 mg | 6/206 | 4/183 |
| Galcanezumab 240 mg | 0/220 | 4/185 |
The reported safety data are counts of participants with serious adverse events and participants at risk. They should not be confused with the primary efficacy analysis population or with the total enrollment of 862. The ClinicalTrials.gov record does not provide a formal comparative statistical analysis of serious adverse events, so this page does not calculate one.
15. Confidence Intervals and Statistical Precision
Confidence intervals appear throughout the posted efficacy analyses. They are particularly useful here because the point estimate alone does not communicate how precisely the treatment effect has been estimated.
| Outcome | Comparison | Estimate | 95% CI |
|---|---|---|---|
| Monthly migraine headache days | 120 mg vs placebo | -1.92 | -2.48 to -1.37 |
| Monthly migraine headache days | 240 mg vs placebo | -1.76 | -2.31 to -1.20 |
| MSQ Role Function Restrictive | 120 mg vs placebo | 7.74 | 5.20 to 10.28 |
| MSQ Role Function Restrictive | 240 mg vs placebo | 7.40 | 4.83 to 9.97 |
| Headache hours | 120 mg vs placebo | -13.98 | -18.99 to -8.97 |
| Headache hours | 240 mg vs placebo | -13.64 | -18.68 to -8.60 |
| MIDAS total score | 120 mg vs placebo | -6.29 | -9.45 to -3.13 |
| MIDAS total score | 240 mg vs placebo | -5.19 | -8.39 to -1.98 |
The intervals for the continuous efficacy outcomes all exclude zero in the analyses posted on ClinicalTrials.gov. That is consistent with the reported superiority P-values. However, a confidence interval crossing or not crossing zero is not itself a measure of clinical importance. Clinical interpretation requires understanding the endpoint's scale and the magnitude of the observed difference.
16. Missing Data and Analysis Population
The primary efficacy population was defined as all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value. This criterion is important because it determines who contributes to the reported mixed-effects analysis.
Randomization
Randomization establishes the treatment groups before post-randomization outcomes are observed and is central to the causal comparison.
At least one dose
The registry analysis population excludes randomized participants who did not receive at least one dose.
Baseline measurement
A qualifying baseline value is required for the primary analysis population.
Post-baseline measurement
At least one post-baseline value is required. The ClinicalTrials.gov record does not specify the complete missing-data assumptions or imputation rules used by the model.
This distinction illustrates why "enrollment" and "analysis population" are not interchangeable. The registry reports 862 enrolled participants, while the primary analysis population has additional eligibility requirements based on treatment exposure and available outcome measurements.
17. What the Primary Effect Estimates Do — and Do Not — Mean
The primary estimate of -1.92 for 120 mg is a modeled difference in mean change from baseline in monthly migraine headache days between the galcanezumab and placebo groups.
It does not mean that every participant had exactly 1.92 fewer migraine headache days. It also does not describe the probability that an individual participant will respond.
The responder odds ratio of 2.63 for the ≥50% threshold represents a ratio of odds, not a ratio of probabilities. It therefore should not be described as saying that 63% more participants responded.
The reported P < .001 for the two primary comparisons indicates strong statistical evidence against the relevant null hypothesis under the reported testing framework. It does not quantify effect size, probability of replication, or probability that the null hypothesis is true.
A 95% confidence interval describes uncertainty in the estimated treatment effect under the statistical model and sampling framework. It is not a prediction interval for individual participants.
18. Multiplicity and Multiple Comparisons
EVOLVE-1 contains multiple statistical comparisons and multiple secondary outcomes. The ClinicalTrials.gov record classifies the efficacy analyses as superiority and report nominal P-values, but they do not provide a multiplicity-adjustment strategy or an alpha hierarchy.
| Analysis family | Reported information | Interpretive implication |
|---|---|---|
| Primary endpoint | Two dose comparisons against placebo | Two primary treatment comparisons are reported. |
| Responder endpoint | ≥50%, ≥75%, and 100% thresholds for two doses | Multiple secondary comparisons are present. |
| Quality-of-life endpoint | Two dose comparisons | Additional secondary testing is present. |
| Other efficacy outcomes | Headache days requiring acute medication, PGI-S, headache hours, MIDAS | Multiple additional treatment comparisons are reported. |
| ADA outcomes | TE ADA Positive and neutralizing antibodies for two doses | Multiple categorical tests are reported. |
The appropriate interpretation of a P-value depends partly on whether it was part of a prespecified multiplicity-controlled testing hierarchy. Because that information is absent from the ClinicalTrials.gov record, the page reports the posted P-values without assigning them a stronger confirmatory status than the registry supports.
19. Limitations
- Registry-level detail: The ClinicalTrials.gov record provides the reported statistical methods and estimates but do not include the complete statistical analysis plan or model specification.
- Mixed-model specification: The registry identifies a mixed-effects model but does not provide the complete fixed-effects structure, covariance structure, or estimation details in the ClinicalTrials.gov record.
- Missing-data assumptions: The analysis population requires at least one post-baseline value, but the ClinicalTrials.gov record does not specify the complete assumptions or sensitivity analyses used for missing observations.
- Multiplicity: Numerous primary and secondary comparisons are reported, while the ClinicalTrials.gov record does not specify an alpha-allocation or multiplicity-adjustment strategy.
- Secondary endpoint reporting: Some secondary analyses have effect estimates and confidence intervals, while ADA analyses provide P-values without effect estimates or confidence intervals.
- Registry coding inconsistency: The galcanezumab 240 mg analysis for monthly migraine headache days requiring acute medication is labeled as binary and as an odds ratio despite an estimate and confidence interval that appear numerically to be a mean difference. The registry wording is preserved rather than silently corrected.
- Safety comparisons: Serious adverse-event counts are reported by arm, but no formal comparative safety analysis is reported in the ClinicalTrials.gov record used here.
- Generalizability: The ClinicalTrials.gov record does not contain a detailed baseline-characteristics table, so representativeness cannot be assessed beyond the stated trial population and design.
20. Why This Trial Matters Statistically
EVOLVE-1 is a useful statistical teaching case because it combines randomized treatment allocation with a longitudinal continuous endpoint, responder definitions, quality-of-life measurements, categorical safety-related analyses, and multiple comparisons.
| Concept | How it appears in EVOLVE-1 |
|---|---|
| Randomization | The trial uses randomized allocation to parallel treatment groups. |
| Double masking | The registry classifies the study as double masked. |
| Repeated measurements | The primary endpoint spans baseline through Month 6. |
| Mixed-effects model | Used for the primary monthly migraine headache-day endpoint and several secondary continuous outcomes. |
| Mean difference | Used to quantify differences in modeled continuous outcomes. |
| Odds ratio | Used for reported responder thresholds of ≥50%, ≥75%, and 100% reduction. |
| Fisher exact test | Used for anti-drug antibody categorical comparisons. |
| Confidence intervals | Reported for primary and several secondary effect estimates. |
| P-values | Reported for primary, continuous secondary, and ADA analyses. |
| Multiplicity | Multiple doses, responder thresholds, quality-of-life outcomes, and other secondary endpoints create a multiple-testing problem. |
21. Results Summary
| Outcome family | 120 mg vs placebo | 240 mg vs placebo |
|---|---|---|
| Primary monthly migraine headache days | -1.92 (95% CI -2.48 to -1.37), P < .001 | -1.76 (95% CI -2.31 to -1.20), P < .001 |
| ≥50% responder odds ratio | 2.63 (95% CI 2.05 to 3.37) | 2.48 (95% CI 1.94 to 3.18) |
| ≥75% responder odds ratio | 2.65 (95% CI 2.04 to 3.45) | 2.62 (95% CI 2.01 to 3.41) |
| 100% responder odds ratio | 2.80 (95% CI 1.96 to 4.01) | 2.61 (95% CI 1.81 to 3.75) |
| MSQ Role Function Restrictive | 7.74 (95% CI 5.20 to 10.28), P < .001 | 7.40 (95% CI 4.83 to 9.97), P < .001 |
| Headache hours | -13.98 (95% CI -18.99 to -8.97), P < .001 | -13.64 (95% CI -18.68 to -8.60), P < .001 |
| MIDAS total score | -6.29 (95% CI -9.45 to -3.13), P < .001 | -5.19 (95% CI -8.39 to -1.98), P < .001 |
The statistical pattern is internally coherent across several continuous outcomes: the reported mean differences are accompanied by two-sided 95% confidence intervals and P-values below .001. The responder analyses use odds ratios instead, illustrating why the choice of effect measure should follow the scale and structure of the endpoint.
22. Related Tutorials
Learn more about the methods used in this trial:
23. Related Calculators
24. Sources
- ClinicalTrials.gov: EVOLVE-1, NCT02614183.
- PubMed: PMID 35076090.
- PubMed: PMID 34264500.
- PubMed: PMID 34049484.
- PubMed: PMID 33950375.
- PubMed: PMID 33549036.
Continue through the Clinical Biostats statistical pathway
Explore the underlying concepts used to understand randomized trials, longitudinal outcomes, confidence intervals, categorical tests, odds ratios, and statistical evidence.
25. Record Summary
EVOLVE-1 provides a compact example of how a randomized clinical trial can generate several distinct statistical questions from the same underlying treatment comparison. Its primary endpoint is longitudinal and analyzed with a mixed-effects model, producing mean differences and two-sided 95% confidence intervals. Secondary responder outcomes use odds ratios, while anti-drug antibody outcomes use Fisher exact testing. The result is a useful illustration of why endpoint type determines the appropriate effect measure and statistical method.
The most important interpretive distinction is between effect size, precision, and statistical evidence. The mean differences and odds ratios describe estimated treatment effects; the confidence intervals describe uncertainty around those estimates; and the P-values address evidence under the relevant null hypotheses. None of these quantities alone describes the experience of every individual participant.